Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring
Yumi KatsumeTsuyoshi IsawaYukihiro ToiRyo FukudaYasuteru KondoShunichi SugawaraTatsushi Ootomo
Author information
JOURNALS OPEN ACCESS

2018 Volume 57 Issue 21 Pages 3157-3162

Details
Abstract

Pembrolizumab, a humanized monoclonal IgG4 antibody directed against programmed death-1, is an immune checkpoint inhibitor that has been introduced for the treatment of non-small-cell lung cancer. However, immune checkpoint inhibitors may cause severe immune-related adverse events. We herein present a case of lung cancer with complete atrioventricular block associated with acute myocarditis, which developed 16 days after the administration of pembrolizumab. The clinical course of this case suggested a strong need for close cardiac monitoring when pembrolizumab is administered on an outpatient basis.

Information related to the author
© 2018 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top